Related Experiment Video
Updated: May 8, 2025
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Retrospective Analysis of Sacubitril/Valsartan vs Benazepril for Treating Heart Failure Following Acute Myocardial
Li Zhao1, Yuanyuan Ren1, Donghui Qin2
1Department of Cardiology, The Third Affiliated Hospital of Qiqihar Medical College, Qiqihar, 161000, People's Republic of China.
Insights
Sacubitril/Valsartan significantly improved cardiac function and reduced adverse events in heart failure patients post-acute myocardial infarction (AMI). This treatment offers a safer and more effective alternative to Benazepril for managing post-AMI heart failure.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure following acute myocardial infarction (AMI) is a significant clinical challenge.
- Optimizing treatment strategies is crucial for improving patient outcomes and reducing morbidity.
Purpose of the Study:
- To compare the efficacy of Sacubitril/Valsartan versus Benazepril in patients with heart failure post-AMI.
- To evaluate the impact of these treatments on cardiac function, inflammatory markers, and clinical outcomes.
Main Methods:
- Retrospective analysis of 103 patients with heart failure post-AMI.
- Patients received either Benazepril (control) or Sacubitril/Valsartan (observation) alongside standard care post-percutaneous coronary intervention (PCI).
- Outcomes assessed included cardiac function (LVESV, LVEDD, LVEF), inflammatory markers (hs-CRP, IL-6), NT-proBNP, MACEs, and 6-minute walking distance (6MWD).
Main Results:
- Sacubitril/Valsartan group showed significant improvements in left ventricular function (LVESV, LVEDD, LVEF) and reduced inflammatory markers (hs-CRP, IL-6) and NT-proBNP.
- The observation group experienced a significantly lower incidence of major adverse cardiac events (MACEs) and greater improvement in 6MWD.
- No significant difference in adverse reaction incidence was observed between groups.
Conclusions:
- Sacubitril/Valsartan is a safe and effective treatment for heart failure post-AMI.
- It offers superior benefits in improving cardiac function, reducing inflammation, and enhancing exercise capacity compared to Benazepril.
- The drug also demonstrates a significant reduction in MACE risk, highlighting its therapeutic potential.
Objective:
To retrospectively compare the efficacy of Sacubitril/Valsartan and Benazepril in the treatment of heart failure in patients following acute myocardial infarction.
Methods:
A retrospective analysis of clinical data was conducted for 103 patients with heart failure following acute myocardial infarction admitted to our hospital from January 2021 to January 2024. All patients met complete inclusion and exclusion criteria. Based on the treatment interventions received, they were divided into a control group (n=51) and an observation group (n=52). All patients received percutaneous coronary intervention (PCI) and conventional drug treatment upon admission. The control group received additional treatment with benazepril, while the observation group received Sacubitril/Valsartan on top of the baseline treatment. A comparison was made between the two groups in terms of clinical treatment outcomes, cardiac function indicators [left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDD), left ventricular ejection fraction (LVEF)], levels of inflammatory markers [high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6)], N-terminal pro-B-type natriuretic peptide (NT-proBNP), incidence of adverse reactions, major adverse cardiac events (MACEs), and 6-minute walking distance (6MWD).
Results:
No patients were lost to follow-up. After six months of treatment, the observation group demonstrated significantly greater improvements in left ventricular function parameters (LVESV, LVEDD, and LVEF) and reductions in inflammatory markers (hs-CRP, IL-6) and NT-proBNP levels compared to the control group (P < 0.05). The observation group also had a significantly lower incidence of major adverse cardiac events (MACEs) (11.54% vs 31.37%, P < 0.05) and a greater improvement in 6-minute walking distance (P < 0.05). The incidence of adverse reactions was comparable between the two groups (P > 0.05).
Conclusion:
Sacubitril/Valsartan is a safe and effective treatment for heart failure post-AMI, offering significant improvements in cardiac function, inflammatory response, exercise capacity, and a reduction in MACE risk.
More Related Videos
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:22Heart Failure Drugs: Diuretics
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
01:25Antihypertensive Drugs: Direct Renin Inhibitors